• Citer

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

par Curigliano, Giuseppe;De Laurentiis, Michelino;Harbeck, Nadia;Kuemmel, Sherko;Garcia-Sáenz, José;Sánchez-Bayona, Rodrigo;Rea, Daniel William;Okines, Alicia;Pistilli, Barbara;Sears, Ellen;Maitland, Jessica;Kloss, Sebastian;Wasserman, Tomer;Ignatiadis, Michail
Référence ESMO Open, 11, 10, 108535
Publication Publié, 2026-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting
Auteur:	Curigliano, Giuseppe; De Laurentiis, Michelino; Harbeck, Nadia; Kuemmel, Sherko; Garcia-Sáenz, José; Sánchez-Bayona, Rodrigo; Rea, Daniel William; Okines, Alicia; Pistilli, Barbara; Sears, Ellen; Maitland, Jessica; Kloss, Sebastian; Wasserman, Tomer; Ignatiadis, Michail
Informations sur la publication:	ESMO Open, 11, 10, 108535
Statut de publication:	Publié, 2026-10
Sujet CREF:	Généralités
Mots-clés:	breast cancer
	elacestrant
	ESR1 mutation
	metastatic breast cancer
	real-world data
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2059-7029
	info:doi/10.1016/j.esmoop.2026.108535
	info:pii/S2059702926024804
	info:scp/105050245067
	info:pmid/42735454